Cost-effectiveness analysis of gender-stratified Plasmodium vivax treatment strategies using available g6pd diagnostics to accelerate access to radical cure
Tafenoquine has been licensed for the single-dose radical cure of Plasmodium vivax in adults; however, it is only recommended in patients with > 70% of normal glucose-6-phosphate dehydrogenase (G6PD) activity. Because this may hinder widespread use, we investigated gender-based treatment strategi...
Main Authors: | Devine, A, Howes, RE, Price, DJ, Moore, KA, Ley, B, Simpson, JA, Dittrich, S, Price, RN |
---|---|
Format: | Journal article |
Sprog: | English |
Udgivet: |
American Society of Tropical Medicine and Hygiene
2020
|
Lignende værker
-
Expanding the use of primaquine for the radical cure of Plasmodium vivax
af: Price, RN, et al.
Udgivet: (2018) -
Progress towards safer and more effective radical cure of Plasmodium vivax
af: Price, RN
Udgivet: (2024) -
Global economic costs due to Plasmodium Vivax malaria treatment and the cost-benefit of radical cure
af: Devine, A, et al.
Udgivet: (2018) -
Improving the radical cure of Plasmodium vivax malaria.
af: Price, R
Udgivet: (2014) -
Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study
af: Devine, A, et al.
Udgivet: (2021)